关于我们|杭州圣域生物医药科技有限公司

Company

To deliver the first-in-class medicines to cancer patients

SynRx Therapeutics is an innovative R&D company focusing on the development of novel anti-tumor drugs using synthetic lethality approaches. We are currently exploring several first-in-class anti-tumor compounds, and preclinical studies are in progress .

Development strategy

Using synthetic lethality strategies, we are developing the first-in-class anti-cancer agents.

Aug.

SynRx Therapeutics was founded

2021

Jan.

The biology research and development center 
was established

2022

Mar.

Inauguration of the Shanghai Branch

2022

Advantage

Synthetic lethality strategy

Synthetic lethality strategy allows us to cure cancers with mutations on tumor suppressor genes. In particular, we are able to indirectly target those “undruggable” tumor suppressors to drastically expand the scope of cancer therapeutics. In combination with other types of cancer therapies, such as tumor immunotherapy, our approach also has the potential to overcome cancer drug resistance caused by secondary mutations arising from conventional cancer therapies. In short, synthetic lethality strategies specifically kill cancer cells with a clear biomarker and create a clear pathway for cancer treatment.
Focusing on DNA damage repair pathways

Genomic instability is a hallmark of tumor cells and is often caused by DNA damage repair defects. To make use of this weakness, we are developing novel approaches to not only selectively kill tumor cells but also leave normal cells unharmed. Thus, our goal is to obtain maximal therapeutic window with little side-effect.
Leading the development of original targets

Original research conducted in Dr./Professor Yu’s lab has opened a new field of DNA damage repair has helped build the foundation of the company's "source of innovation" on drug development. We continue to collaborate with well recognized leaders in academia and industry to conduct cutting-edge research.

Leadership

Xiaochun Yu Professor

Founder and Chairman

Professor and Associate Dean, School of Life Sciences, Westlake University

Professor, University of Michigan Medical School

M.D., Beijing Medical University; Ph.D, Kurume University, Japan

Published more than 100 academic papers

Song Liu PhD

Co-founder and CEO

Executive director of a well-known healthcare professional investment fund, invests and manages more than 20 biotechnology companies, many of which have successfully listed in Hong Kong and the US stock markets or completed mergers and acquisitions

Investigator of Medicinal Chemistry, Novartis Institutes of Biomedical Research, small molecule research and development on epigenetics

PhD in chemistry, University of Chicago

About Us Technology & Products News Careers

Business Development bd@synrx.cn

Careers hr@synrx.cn

Address @ Room 201, Building 4, 1390 Cangxing Street, Cangqian Subdistrict, Yuhang District, Hangzhou, Zhejiang @ Room 303, No.1, Lane 88, Shengrong Road, Zhangjiang High-Tech Park, Pudong New District, Shanghai

0571-86360796

Contact